Wuhan Createrna Science and Technology Co., Ltd
Createrna is an innovative drug research and development company dedicated to providing high-quality professional products and services for human health. They focus on advancing treatment options from research to product launch, with a strong emphasis on scientific research, pipeline development, and clinical trials. The company aims to improve health outcomes and has built a comprehensive R&D system covering the entire drug development process.
Industries
Nr. of Employees
medium (51-250)
Wuhan Createrna Science and Technology Co., Ltd
Wuhan Createrna Science and Technology Co., Ltd.
Products
Clinical-stage drug development pipeline
A portfolio of internally developed therapeutic candidates across cardiovascular, kidney, respiratory and inflammatory/immune indications at stages from preclinical/IND to Phase II clinical trials.
Clinical-stage drug development pipeline
A portfolio of internally developed therapeutic candidates across cardiovascular, kidney, respiratory and inflammatory/immune indications at stages from preclinical/IND to Phase II clinical trials.
Services
End-to-end research and development support from candidate identification through preclinical development and clinical study execution, provided via internal programs and external collaborations.
End-to-end research and development support from candidate identification through preclinical development and clinical study execution, provided via internal programs and external collaborations.
Expertise Areas
- Clinical trial management (Phase I–III)
- Preclinical development and IND-enabling studies
- Candidate screening and lead optimization
- Therapeutic-area drug development (cardiovascular, renal, respiratory, inflammatory/immune)
Key Technologies
- Small-molecule discovery
- Candidate screening assays
- Preclinical pharmacology and toxicology studies
- IND-enabling study execution
News & Updates
The application for clinical trial of MY008211A tablet was officially accepted by the State Food and Drug Administration
Createrna's three new drugs under research have received clinical trial approval.
The first patient has been enrolled in the Phase II clinical trial of QR052107B for subacute cough.
All subjects have been enrolled in the Phase II clinical trial of the innovative drug QR12000.
The first patient has been enrolled in the Phase II clinical trial of MY004567 for moderate to severe active rheumatoid arthritis.
The first patient has been enrolled in the Phase II clinical trial of MY008211A for paroxysmal nocturnal hemoglobinuria.
The application for clinical trial of MY008211A tablet was officially accepted by the State Food and Drug Administration
Createrna's three new drugs under research have received clinical trial approval.
The first patient has been enrolled in the Phase II clinical trial of QR052107B for subacute cough.
All subjects have been enrolled in the Phase II clinical trial of the innovative drug QR12000.
The first patient has been enrolled in the Phase II clinical trial of MY004567 for moderate to severe active rheumatoid arthritis.
The first patient has been enrolled in the Phase II clinical trial of MY008211A for paroxysmal nocturnal hemoglobinuria.